Remove 2023 Remove Leads Remove Medical science
article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). And in 2023, these investments will hopefully pay off. Leading companies will empower their teams to act quickly, compliantly, and with a unified view of the HCP.”.

article thumbnail

Manufacturing challenges set back development progress of cell therapies in oncology

Pharmaceutical Technology

Meanwhile, the drug's closest TIL competitor, Iovance Biotherapeutics’ lifileucel, has begun a rolling BLA for advanced melanoma patients and could reach the market as early as Q3 2023. In April this year, the FDA provided new feedback on the potency assays, which Iovance indicated will be addressed in the latest BLA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. This trial is anticipated to begin in the second half of 2023.

article thumbnail

Why R&D innovation holds the key to greater patient impact

European Pharmaceutical Review

Cancer remains a global threat with around 10 million people dying from the disease each year worldwide, making it the second leading cause of death. Previously, he spent more than 10 years at Roche in multiple positions within medical affairs. cited 2023 Apr 4]. 2019 [cited 2023 Apr 4]. cited 2023 Apr 4].

Patients 105
article thumbnail

Recurrent drug shortages signal onerous outlook for cardiovascular care

Pharmaceutical Technology

The Australian Department of Health and Aged Care published a similar statement on August 25, stating that tenecteplase shortages will likely affect the country until the end of 2023. Also, substitution can lead to further shortages, he adds. Dobutamine is used in the acute treatment of heart failure.

Medicine 111
article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. More info can be found at the Biomed Israel website.

article thumbnail

The role of artificial intelligence or machine learning in conducting systematic literature reviews now and in future

Clarivate

One recent review reported a 77% reduction in human screening time (Van Dijk, 2023), however authors did acknowledge that a substantial period of time was required for researchers to become familiar with using the AI tool in the first place. EUROPEAN PARLIAMENT, 2023: EU AI Act: first regulation on artificial intelligence. Bucsan, C.